

CURRICULUM VITAE

IDENTIFYING INFORMATION

Name : Kazushi Numata

EDUCATIONAL HISTORY

1993 M.D., Ph. D. Yokohama City University, Yokohama, Japan

(Thesis: Numata K, Tanaka K, Mitsui K, Morimoto M, Inoue, S., Yonezawa, H.: Flow characteristics of hepatic tumors at color Doppler sonography: Correlation with arteriographic findings. Am J Roentgenol 160:515-521,1993)

BIBLIOGRAPHY (PUBLICATIONS)

1. Tanaka K., Inoue S., Numata K., Okazaki H., Nakamura S., Takamura Y. Very-low-calorie diet induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity. Metabolism 39:892-896,1990.
2. Tanaka K, Inoue S, Shiraki J, Shishido T, Saito M, Numata K, Takamura Y: Age-related decrease in plasma growth hormone: response to growth hormone-releasing hormone, arginine, and L-dopa in obesity. Metabolism 40:1257-1262,1991.
3. Tanaka K, Inoue S, Numata K, Takamura, Y., Takebayashi, S. Ohaki, Y., Misugi, K. Color Doppler sonography of hepatocellular carcinoma before and after treatment by transcatheter arterial embolization. Am J Roentgenol 158:541-546,1992.
4. Tanaka K, Nakamura S, Numata K, Okazaki, H., Endo, O., Inoue, S., Takamura, Y., Sugiyama, M., Ohaki, Y. Hepatocellular carcinoma: Treatment with percutaneous ethanol injection and transcatheter arterial embolization. Radiology 185:457-460,1992.
5. Numata K, Tanaka K, Saito M, Shishido T, Inoue S: Very low calorie diet-induced weight loss reverses exaggerated insulin secretion in response to glucose, arginine and glucagon in obesity. International Journal of Obesity 17:103-108,1993.

6. Numata K, Tanaka K, Mitsui K, Morimoto M, Inoue, S., Yonezawa. H.: Flow characteristics of hepatic tumors at color Doppler sonography: Correlation with arteriographic findings. Am J Roentgenol 160:515-521,1993.
7. Tanaka K, Numata K, Okazaki H, Nakamura, S., Inoue, S., Takamura, Y. Diagnosis of portal vein thrombosis in patients with hepatocellular carcinoma: Efficacy of color Doppler sonography compared with angiography. Am J Roentgenol 160:1279-1283,1993.
8. Tanaka K, Mitsui K, Morimoto M, Numata K, Inoue S, Takamura Y, Masumura M: Increased hepatic arterial blood flow in acute viral hepatitis:assessment by color Doppler sonography. Hepatology 18:21-27,1993.
9. Kiba T, Tanaka K, Hoshino M, Numata K, Inoue S. Comparison of DNA synthesis of white and brown adipose tissue in rats with ventromedial hypothalamic lesions. Pflugers Arch. Eur. J. Physiol. 424:122-128,1993.
10. Kiba T, Tanaka K, Numata K, Hoshino M, Inoue S. Facilitation of liver regeneration after partial hepatectomy by ventromedial hypothalamic lesions in rats. Pflugers Arch. Eur. J. Physiol.428:26-29,1994.
11. Morimoto M, Numata K, Tanaka K. Rat peripheral mononuclear cell thymidine kinase activity increases during regenerative processes after partial hepatectomy. Journal of Gastroenterology and Hepatology 10:655-661,1995.
12. Kiba T, Tanaka K, Hoshino M, Numata K, Okano K, Inoue S. Ventromedial hypothalamic lesions induce the proliferation of gastrointestinal mucosal cells in the rat. Life Science 57:827-832,1995.
13. Kiba T, Tanaka K, Numata K, Hosino M, Misugi K, Inoue S. Ventromedial hypothalamic lesion-induced vagal hyperactivity stimulates rat pancreatic cell proliferation. Gastroenterology 110:885-893,1996.
14. Numata K, Tanaka K, Kiba T, Morimoto M, Arata S, Kondo M, Sekihara H. Use of hepatic tumor index on color Doppler sonography for differentiating large hepatic tumors. Am J Roentgenol 168:991-995,1997.

15. Saito S, Tanaka K, Kondo M, Morita K, Kitamura T, Kiba T, Numata K, Sekihara H. Plus-and minus-stranded hepatitis G virus RNA in liver tissue and in peripheral blood mononuclear cells. *Biochem Biophys Res Commun* 237:288-291,1997
16. Numata K, Tanaka K, Kiba T, Mitsui K, Saito S, Sekihara H. Hemodynamic changes in hepatic artery after glucose ingestion in healthy subjects and patients with cirrhosis. *J Clin Ultrasound* 26:137-142,1998
17. Tanaka K, Nakamura S, Numata K, Kondo M, Morita K, Kitamura T, Saito S, Kiba T, Okazaki H, Sekihara H. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. *Cancer* 82:78-85,1998
18. Numata K, Tanaka K, Kiba T, Saito S, Shirato K, Kitamura T, Sekihara H : Treatment of hepatic encephalopathy in a cirrhotic patient with a large spontaneous splenorenal shunt: balloon-occluded retrograde transvenous obliteration using ethanolamine oleate. *J Gastroenterol* 33:424-427,1998 1
19. Kiba T, Tanaka K, Numata K, Saito S, Sekihara H :Hepatocyte proliferation in rats after ventromedial hypothalamic lesions: Immunoreactivity pattern of proliferating cell nuclear antigen (PCNA). *J Gastroenterol* 33:523-528,1998
20. Arai T, Numata K, Tanaka K, Kiba T, Kawasaki S, Saito T, Satoh S, Sekihara H: Ocular arterial flow hemodynamics in patients with diabetes mellitus. *J Ultrasound Med* 17:675-681,1998
21. Isozaki T, Kiba T, Numata K, Saito S, Shimamura T, Kitamura T, Morita K, Tanaka K, Sekihara H: Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. *Internal Medicine* 38:17-21,1999 2
22. Numata K, Tanaka K, Kiba T, Morita K, Saito S, Fujii T, Sekihara H. Hepatic arterial resistance after mixed-meal ingestion in healthy subjects and patients with chronic liver disease. *J Clin Ultrasound* 27:239-248,1999
23. Morita K, Tanaka K, Saito S, Kitamura T, Kiba T, Fujii T, Numata K, Sekihara T.

Expression of interferon receptor genes in the liver as a predictor of interferon response in patients with chronic hepatitis C. J.Med.Virol. 58:359-365,1999

24. Numata K, Tanaka K, Kiba T, Morita K, Saito S, Kirikoshi H, Shimamura T, Sekihara H
Correlation between hepatic tumor index on color Doppler sonography and tumor vessels on
arteriography in large hepatocellular carcinomas. Cancer Detect Prev. 23:496-505, 1999

25. Kitamura K, Tanaka K, Morita K, Saito S, Kiba T, Numata K, Sekihara H.
Dehydroepiandrosterone (DHEA) facilitates liver regeneration after partial hepatectomy in rats. Life
Science 65:1747-1756, 1999

26. Kiba T, Saito S, Numata K, Sekihara H. Fas (APO-1/CD95) mRNA is down-regulated in liver
regeneration after hepatectomy in rats. J Gastroenterol 35:34-38, 2000

27. Morita K, Numata K, Tanaka K, Mitsui K, Matsumoto S, Kitamura T, Saito S, Kiba T, Sekihara
H Sonographically guided core-needle biopsy of focal splenic lesions: Report of four cases. J Clin
Ultrasound 28:417-424, 2000 3

28. Shimamura T, Saito S, Morita K, Kitamura T, Morimoto M, Kiba T, Numata K, Tanaka K,
Sekihara H Detection of vascular endothelial growth factor and its receptor expression in human
hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 15:640-646, 2000

29. Shirato K, Numata K, Mitsui K, kitamura T, Morita K, Saito S, Morimoto M, Kiba T, Okazaki H,
Tanaka K, Sekihara H. Color Doppler sonography for evaluating response to transcatheter arterial
embolization and percutaneous ethanol injection therapy and for detecting recurrence of
hepatocellular carcinoma. J Ultrasound Med 19:807-814,2000

30. Umezawa T, Kiba T, Numata K, Saito T, Nakaoka M, Shintani S, Sekihara H.
Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after
administration of irinotecan and 5-fluorouracil in combination to rats.
Anticancer Res. 20:4235-4242, 2000

31. Numata K, Tanaka K, Kiba T, Saito S, Ikeda M, Hara K, Tanaka N, Morimoto M, Iwase S,
Sekihara H. Contrast-enhanced, wide-band harmonic gray-scale imaging of hepatocellular
carcinoma: correlation with helical computed tomographic findings. J Ultrasound Med 20:89-98,
2001

32. Kiba T, Saito S, Numata K, Kon Y, Sekihara H. Expression of apoptosis on rat liver by hepatic vagus hyperactivity after ventromedial hypothalamic lesioning.
Am J Physiol Gastrointest Liver Physiol. 280:G958-G967, 2001
33. Numata K, Tanaka K, Kiba T, Saito S, Isozaki T, Hara K, Morimoto M, Sekihara H, Yonezawa H, Kubota T. Using contrast-enhanced sonography to assess the effectiveness of transcatheter arterial embolization for hepatocellular carcinoma. Am J Roentgenol 176:1199-1205, 2001
34. Kiba T, Numata K, Kitamura T, Morita K, Saito S, Sekihara H. Combination therapy of percutaneous mitoxantron injection, percutaneous ethanol injection, and transcatheter arterial embolization for intrahepatic hepatocellular carcinoma and adrenal metastasis.
Hepatogastroenterology 48:427-431, 2001
35. Arata S, Tanaka K, Okazaki H, Kondo M, Morimoto M, Saito S, Numata K, Nakamura S, Sekihara H. Risk factors for intrahepatic recurrence of large hepatocellular carcinoma in patients treated by combined transcatheter arterial embolization and percutaneous ethanol injection.
Hepatogastroenterology 48:480-485, 2001
36. Kiba T, Numata K, Kirikoshi H, Kamijo S, Nakatani Y, Sekihara H.
A long-term survival case of pancreatic poorly differentiated adenocarcinoma with transcatheter arterial embolization and combination chemotherapy. Hepatogastroenterology 48:1499-1503, 2001
4
37. Numata K, Tanaka K, Kiba T, Matsumoto S, Iwase S, Hara K, Kirikoshi H, Morita K, Saito S, Sekihara H. Nonresectable hepatocellular carcinoma: improved percutaneous ethanol injection therapy guided by CO₂-enhanced sonography. Am J Roentgenol 177:789-798, 2001
38. Hara K, Numata K, Tanaka K, Saito S, Morimoto M, Ikeda M, Iwase S, Matsumoto S, Yonezawa H, Sekihara H. Diagnosis of advanced hepatocellular carcinoma using contrast-enhanced harmonic gray-scale imaging with enhancement agents (Levovist): correlation with helical CT and US angiography. J Med Ultrasonics 28:127-133, 2001
39. Shirato K, Morimoto M, Tomita N, Kokawa A, Sugimori K, Saito T, Numata K, Sekihara H, Tanaka K. Small hepatocellular carcinoma: therapeutic effectiveness of percutaneous radio frequency ablation therapy with a LeVeen needle electrode.

J Ultrasound Med 21:67-76, 2002

40. Matsumoto S, Kiba T, Numata K, Ihata Y, Morita K, Kitamura T, Saito S, Nakatani Y, Tanaka K, Sekihara H. Advanced gastric cancer associated with DIC successfully treated with 5-FU and cisplatin: a case report. Hepatogastroenterology 49:153-156, 2002 5

41. Ozawa Y, Numata K, Tanaka K, Ueno N, Kiba T, Hara K, Morimoto M, Sakaguchi T, Sekihara H, Kubota T, Shimada H, Nakatani Y. Contrast-enhanced sonography of small pancreatic mass lesions. J Ultrasound Med 21:983-991, 2002

42. Shirato K, Morimoto M, Tomita N, Kokawa A, Sugimori K, Saito T, Numata K, Sekihara H, Tanaka K. Hepatocellular carcinoma: therapeutic experience with percutaneous ethanol injection under real-time contrast-enhanced color Doppler sonography with the contrast agent Levovist. J Ultrasound Med 21:1015-1022, 2002

43. Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, Tanaka K, Sekihara S. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res. 24:228, 2002.

44. Numata K, Isozaki T, Ozawa Y, Sakaguchi T, Kiba T, Kubota T, Ito A, Sugimori K, Shirato K, Morimoto M, Tanaka K. Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma AJR Am J Roentgenol 180:143-149, 2003

45. Kubota T, Sekido H, Morioka D, Tanaka K, Endo I, Togo S, Saitoh S, Numata K, Tanaka K, Sekihara H, Matsunami H, Tanaka K, Shimada H. Acute hepatic failure with deep hepatic coma treated successfully by high-flow continuous hemodiafiltration and living-donor liver transplantation: a case report. Transplant Proc. 35:394-396, 2003. 6

46. Kiba T, Numata K, Saito S. Neostigmine and polyethylene glycol electrolyte solution for the therapy of acute hepatic encephalopathy with liver cirrhosis and ascites. Hepatogastroenterology 50:823-826, 2003

47. Morimoto M, Shirato K, Sugimori K, Kokawa A, Tomita N, Saito T, Imada T, Tanaka N, Nozawa A, Numata K, Tanaka K. Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with

hepatocellular carcinoma. AJR Am J Roentgenol. 181:65-69, 2003

48. Isozaki T, Numata K, Kiba T, Hara K, Morimoto M, Sakaguchi T, Sekihara H, Kubota T, Shimada H, Morizane T, Tanaka K. Differential diagnosis of hepatic tumors by using contrast enhancement patterns at US. Radiology 229: 798-805, 2003

49. Numata K, Ozawa Y, Kobayashi N, Kubota T, Akinori N, Nakatani Y, Sugimori K, Imada T, Tanaka K. Contrast-enhanced sonography of autoimmune pancreatitis: comparison with pathologic findings. J Ultrasound Med. 23:199-206, 2004.

50. Tanaka K, Numata K, Morimoto M, Shirato K, Saito S, Imada T, Arata S, Sugiyama M. Elevated resistive index in the hepatic artery as a predictor of fulminant hepatic failure in patients with acute viral hepatitis: a prospective study using Doppler ultrasound. Dig Dis Sci. 49:833-842, 2004.

51. Sugimori K, Morimoto M, Shirato K, Kokawa A, Tomita N, Numata K, Saito T, Tanaka K. Retrograde Transvenous Obliteration of Gastric Varices Associated with Large Collateral Veins or a Large Gastrorenal Shunt. J Vasc Interv Radiol 16:113-118, 2005.

52. Morimoto M, Nozawa A, Numata K, Shirato K, Sugimori K, Kokawa A, Tomita N, Saitou T, Nakatani Y, Imada T, Tanaka K. Evaluation using contrast-enhanced harmonic gray scale sonography after radio frequency ablation of small hepatocellular carcinoma: sonographic-histopathologic correlation. J Ultrasound Med. 24:273-283, 2005

53. Numata K, Ozawa Y, Kobayashi N, Kubota T, Shimada H, Nozawa A, Nakatani Y, Sugimori K, Matsuo K, Imada T, Tanaka K. Contrast-enhanced sonography of pancreatic carcinoma: correlations with pathological findings. J Gastroenterol. 40:631-640, 2005.

54. Sugimori K, Nozawa A, Morimoto M, Shirato K, Kokawa A, Saito T, Numata K, Tanaka K. Extension of radiofrequency ablation of the liver by transcatheter arterial embolization with iodized oil and gelatin sponge: results in a pig model. J Vasc Interv Radiol. 16:849-856, 2005.

55. Numata K, Isozaki T, Morimoto M, Sugimori K, Kunisaki R, Morizane T, Tanaka K. Prospective study of differential diagnosis of hepatic tumors by pattern-based classification of contrast-enhanced sonography. World J Gastroenterol 12:6290-6298, 2006

56. Numata K, Morimoto M, Isozaki T, Sugimori K, Oka H, Matsuo K, Shimada H, Imada T.

Use of accumulation images obtained by arterial phase contrast-enhanced harmonic grayscale sonography to evaluate tumor vessels in focal nodular hyperplasia and other hepatic tumors.

J Med Ultrasonics 34:3-10, 2007

57. Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, Hirasawa K, Koh R, Nihonmatsu H, Tanaka K. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007;13(7):1003-1009

58. Numata K, Oka H, Morimoto M, Sugimori K, Kuisak R, Nihonmatsu H, Matsuo K, Nagano Y, Nozawa A, Tanaka K. Differential diagnosis of gallbladder diseases using contrast-enhanced harmonic gray-scale sonography. J Ultrasound Med 26(6):763-774, 2007

59. Numata K, Morimoto M, Ogura T, Sugimori K, Takebayashi S, Okada M, Tanaka K. Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med 27:381–392, 2008

60. Kawasaki S, Aoki K, Hasegawa O, Numata K, Tanaka K, Shibata N, Shimada S, Okamura A, Terauchi Y. Sonographic evaluation of visceral fat by measuring para- and perirenal fat. J Clinical Ultrasound 36:129-33, 2008

61. Luo W, Numata K, Morimoto M, Oshima T, Nozaki A, Okada M, Takebayashi T, Zhou X, Tanaka K. Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. Eur J Radiol. 2010 Jul;75(1):91-7.

62. Luo W, Numata K, Morimoto M, Nozaki A, Nagano H, Sugimori K, Tanaka K. Three-dimensional contrast-enhanced sonography of vascular patterns of focal liver tumors: pilot study of visualization methods. AJR Am J Roentgenol 2009; 192(1):165-73.

63. Luo W, Numata K, Morimoto M, Kondo M, Takebayashi S, Okada M, Morita S, Tanaka K. Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. Radiology 2009; 251:287-295.

64. Luo W, Numata K, Kondo M, Morimoto M, Sugimori K, Hirasawa K, Nozaki A, Tanaka K. Sonazoid-enhanced ultrasonography for evaluating enhancement patterns of focal liver tumors in the late phase by intermittent imaging with a high mechanical index. J Ultrasound Med 2009;

65. Luo W, Numata K, Morimoto M, Nozaki A, Nagano Y, Sugimori K, Zhou X, Tanaka K. Clinical utility of contrast-enhanced three-dimensional ultrasound imaging with Sonazoid: findings on hepatocellular carcinoma lesions. *Eur J Radiol.* 2009 Dec;72(3):425-31.
66. Morimoto M, Numata K, Nozaki A, Tanaka K. Prognosis following non-surgical second treatment in patients with recurrent hepatocellular carcinoma after percutaneous ablation therapy. *Liver Int.* 2009 Mar;29(3):443-448.
67. Kondo M, Morimoto M, Numata K, Nozaki A, Tanaka K. Hepatic Arterial Infusion Therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. *Jpn J Clin Oncol.* 2010; 42: 69-75.
68. Nozaki A, Numata K, Morimoto M, Kondo M, Sugimori K, Morita S, Miyajima E, Ikeda M, Kato N, Maeda S, Tanaka K. Hydroxyurea suppresses HCV replication in humans: a Phase I trial of oral hydroxyurea in chronic hepatitis C patients. *Antivir Ther.* 2010;15:1179-83
69. Inagaki D, Oshima T, Yoshihara K, Tamura S, Kanazawa A, Yamada T, Yamamoto N, Sato T, Shiozawa M, Morinaga S, Akaike M, Fujii S, Numata K, Kunisaki C, Rino Y, Tanaka K, Masuda M, Imada T. Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer. *Anticancer Res.* 2010;30:4127-30.
70. Morimoto M, Numata K, Nozawa A, Kondo M, Nozaki A, Nakano M, Tanaka K. Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. *J Vasc Interv Radiol.* 2010;21:1716-24.
71. Kawasaki S, Hasegawa O, Satoh S, Numata K, Terauchi Y. Sonographic assessment of fatty liver infiltration using the measurement of para- and perirenal fat thickness. *J Clin Ultrasound.* 2010;38:470-4.
72. Yamada T, Oshima T, Yoshihara K, Tamura S, Kanazawa A, Inagaki D, Yamamoto N, Sato T, Fujii S, Numata K, Kunisaki C, Shiozawa M, Morinaga S, Akaike M, Rino Y, Tanaka K, Masuda M, Imada T. Overexpression of MMP-13 gene in colorectal cancer with liver metastasis. *Anticancer Res.* 2010 Jul;30(7):2693-9.

73. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. *Cancer*. 2010;116:5452-60.
74. Numata K, Luo W, Morimoto M, Kondo M, Kunishi Y, Sasaki T, Nozaki A, Tanaka K. Contrast-enhanced ultrasound of hepatocellular carcinoma. *World J Radiol* 2010; 2(2): 68-82
75. Nozaki A, Morimoto M, Kondo M, Oshima T, Numata K, Fujisawa S, Kaneko T, Miyajima E, Morita S, Mori K, Ikeda M, Kato N, Tanaka K. Hydroxyurea as an inhibitor of hepatitis C virus RNA replication. *Arch Virol*. 2010;155:601-5.
76. Morimoto M, Numata K, Kondo M, Nozaki A, Hamaguchi S, Takebayashi S, Tanaka K. C-arm cone beam CT for hepatic tumor ablation under real-time 3D imaging. *AJR Am J Roentgenol*. 2010; 194(5):W452-454.
77. Luo W, Numata K, Morimoto M, Nozaki A, Ueda M, Kondo M, Morita S, Tanaka K. Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies. *World J Gastroenterol* 2010; 16:2109-2119.
78. Numata K, Fukuda H, Ohto M, Ito R, Nozaki A, Kondou M, Morimoto M, Karasawa E, Tanaka K. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocellular carcinoma by three-dimensional sonography with a perflubutane-based contrast agent. *Eur J Radiol*. 2010; 75: e67-e75.
79. Fukuda H, Numata K, Nozaki A, Morimoto M, Kondo M, Tanaka K, Maeda S, Yamagata J, Ohto M, Ito R, Sakamoto A, Zhu H, Wang ZB. Usefulness of US-CT 3D dual imaging for the planning and monitoring of hepatocellular carcinoma treatment using HIFU. *Eur J Radiol*. 2011;80:e306-10.
80. Fukuda H, Numata K, Nozaki A, Kondo M, Morimoto M, Tanaka K, Ito R, Ohto M, Ishibashi Y, Oshima N, Ito A, Zhu H, Wang ZB. Hyperecho in ultrasound images during high-intensity focused ultrasound ablation for hepatocellular carcinomas. *Eur J Radiol*. 2011;80:e571-5.

81. Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A, Kobayashi S, Ohkawa S, Okuse C, Morita S, Taguri M, Tanaka K. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. *Hepatol Res.* 2011; 41: 296-302.
82. Oshima T, Takenoshita S, Akaike M, Kunisaki C, Fujii S, Nozaki A, Numata K, Shiozawa M, Rino Y, Tanaka K, Masuda M, Imada T. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. *Oncol Rep.* 2011;25:1439-46.
83. Hirasawa K, Kokawa A, Oka H, Yahara S, Sasaki T, Nozawa A, Morimoto M, Numata K, Taguri M, Morita S, Maeda S, Tanaka K. Risk assessment chart for curability of early gastric cancer with endoscopic submucosal dissection. *Gastrointest Endosc* 2011;74:1268-75
84. Fukuda H, Numata K, Nozaki A, Morimoto M, Kondo M, Tanaka K, Maeda S, Ohto M, Ito R, Zhu H, Wang ZB. Findings of multidetector row computed tomography of HCCs treated by HIFU ablation. *Eur J Radiol* 2012; 81:e239-43.
85. D'Onofrio M, Barbi E, Dietrich CF, Kitano M, Numata K, Sofuni A, Principe F, Gallotti A, Zamboni GA, Mucelli RP. Pancreatic multicenter ultrasound study (PAMUS). *Eur J Radiol* 2012; 81:630-8.
86. Kunishi Y, Numata K, Morimoto M, Kondo M, Okada M, Maeda S, Kaneko T, Tanaka K. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. *AJR Am J Roentgenol* 2012;198: 106-114
87. Morimoto M, Numata K, Nozaki A, Kondo M, Moriya S, Taguri M, Morita S, Konno M, Sugo A, Miyajima E, Maeda S, Tanaka K. Novel Lens culinaris agglutinin-reactive fraction of α -fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α -fetoprotein concentrations. *Int J Clin Oncol.* 2012;17:373-9.
88. Numata K, Fukuda H, Morimoto M, Kondo M, Nozaki A, Oshima T, Okada M, Takebayashi S, Maeda S, Tanaka K. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma. *Eur J Radiol* 2012; 81: 2746– 2753

89. Morimoto M, [Numata K](#), Moriya S, Kondo M, Nozaki A, Morioka Y, Maeda S, Tanaka K. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. *Anticancer Res.* 2012; 32:619-23.
90. Kokudo N, Nakajima J, Hatano E, [Numata K](#). Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (nexavar®). *Clin Drug Investig.* 2012;32 Suppl 2:25-35.
91. Okada M, Ishii K, [Numata K](#), Hyodo T, Kumano S, Kitano M, Kudo M, Murakami T. Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function? *Hepatobiliary Pancreat Dis Int.* 2012 Jun;11(3):307-13
92. Takizawa K, [Numata K](#), Morimoto M, Kondo M, Nozaki A, Moriya S, Ishii T, Oshima T, Fukuda H, Okada M, Takebayashi S, Maeda S, Tanaka K. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. *Eur J Radiol.* 2013 Sep;82(9):1471-80.
93. Morimoto M, [Numata K](#), Kondo M, Moriya S, Morita S, Maeda S, Tanaka K. Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: a prospective cohort study. *Eur J Radiol.* 2013 Mar;82(3):497-503.
94. Okabe N, Morimoto M, Kondo M, Moriya S, Numata K, Maeda S, Tanaka K. Efficacy of chemoembolization for recurrent HCC after curative ablation therapy. *Hepatogastroenterology.* 2013 May;60(123):395-99.
95. Shimoyama Y, Nozaki A, Morimoto M, Moriya S, Kondo M, Fukuda H, [Numata K](#), Miyajima E, Oba MS, Taguri M, Morita S, Maeda S, Tanaka K. Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C. *Hepatol Res.* 2013 Sep;43(9):919-24.
96. Moriya S, Morimoto M, [Numata K](#), Nozaki A, Shimoyama Y, Kondo M, Nakano M, Maeda S, Tanaka K. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma. *Anticancer Res.* 2013 Mar;33(3):997-1001.
97. Koh R, Hirasawa K, Yahara S, Oka H, Sugimori K, Morimoto M, [Numata K](#), Kokawa A, Sasaki T, Nozawa A, Taguri M, Morita S, Maeda S, Tanaka K. Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms. *Gastrointest Endosc.* 2013 Sep;78(3):476-83.
98. Arata S, Nozaki A, Takizawa K, Kondo M, Morimoto M, [Numata K](#), Hayashi S, Watanabe T, Tanaka Y, Tanaka K. Hepatic failure in pregnancy successfully treated by online

hemodiafiltration: Chronic hepatitis B virus infection without viral genome mutation.

Hepatol Res. **43**(12):1356-1360, 2013.

7

99. Fukuda H, Numata K, Nozaki A, Kondo M, Morimoto M, Maeda S, Tanaka K, Ohto M, Ito R, Ishibashi Y, Oshima N, Ito A, Zhu H, Wang ZB. High-intensity focused ultrasound ablation assisted using color Doppler imaging for the treatment of hepatocellular carcinomas. *Abdom Imaging*. **38**(6):1263-1268, 2013
100. Sato T, Oshima T, Yamamoto N, Yamada T, Hasegawa S, Yukawa N, Numata K, Kunisaki C, Tanaka K, Shiozawa M, Yoshikawa T, Akaike M, Rino Y, Imada T, Masuda M. Clinical significance of SPARC gene expression in patients with gastric cancer. *J Surg Oncol*. 2013 Nov;108(6):364-8.
101. Numata K, Fukuda H, Miwa H, Ishii T, Moriya S, Kondo M, Nozaki A, Morimoto M, Okada M, Takebayashi S, Maeda S, Nozawa A, Nakano M, Tanaka K. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. *Eur J Radiol*. 2014 Jan;83(1):95-102.
102. Sasaki T, Kunisaki R, Kinoshita H, Yamamoto H, Kimura H, Hanzawa A, Shibata N, Yonezawa H, Miyajima E, Sakamaki K, Numata K, Tanaka K, Maeda S. Use of color Doppler ultrasonography for evaluating vascularity of small intestinal lesions in Crohn's disease: correlation with endoscopic and surgical macroscopic findings. *Scand J Gastroenterol*. 2014 Mar;49(3):295-301.
103. Sasaki T, Kunisaki R, Kinoshita H, Kimura H, Koderia T, Nozawa A, Hanzawa A, Shibata N, Yonezawa H, Miyajima E, Morita S, Fujii S, Numata K, Tanaka K, Tanaka M, Maeda S. Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn's disease. *BMC Res Notes*. 2014 Jun 14;7:363. doi: 10.1186/1756-0500-7-363.
104. Kaneko T, Sugimori K, Shimizu Y, Miwa H, Kameta E, Koh R, Numata K, Tanaka K, Maeda S. Efficacy of plastic stent placement inside bile ducts for the treatment of unresectable malignant hilar obstruction (with videos). *J Hepatobiliary Pancreat Sci*. 2014 May;21(5):349-55. doi: 10.1002/jhbp.41. Epub 2013 Oct 7.
105. Oshima T, Yoshihara K, Aoyama T, Hasegawa S, Sato T, Yamamoto N, Akito N, Shiozawa M, Yoshikawa T, Numata K, Rino Y, Kunisaki C, Tanaka K, Akaike M, Imada T, Masuda M. Relation of INHBA Gene Expression to Outcomes in Gastric Cancer after Curative Surgery. *Anticancer Res*. 2014 May;34(5):2303-9.
106. Yamada T, Oshima T, Yoshihara K, Sato T, Nozaki A, Shiozawa M, Ota M, Yoshikawa T, Akaike M, Numata K, Rino Y, Kunisaki C, Tanaka K, Imada T, Masuda M. Impact of overexpression of Sushi repeat-containing protein X-linked 2 gene on outcomes of gastric cancer. *J Surg Oncol*. 2014 Jun;109(8):836-40.

107. Fukuda H, Numata K, Moriya S, Shimoyama Y, Ishii T, Nozaki A, Kondo M, Morimoto M, Maeda S, Sakamaki K, Morita S, Tanaka K. Hepatocellular Carcinoma: Concomitant Sorafenib Promotes Necrosis after Radiofrequency Ablation-Propensity Score Matching Analysis. *Radiology*. 2014 Aug;272(2):598-604
108. Okada M, Wakayama T, Yada N, Hyodo T, Numata K, Kagawa Y, Nishiyama D, Miyakoshi K, Murakami T. Optimal flip angle of Gd-EOB-DTPA-enhanced MRI in patients with hepatocellular carcinoma and liver metastasis. *Abdom Imaging*. 2014 Aug;39(4):694-701.
109. Miwa H, Numata K, Sugimori K, Kaneko T, Sakamaki K, Ueda M, Fukuda H, Tanaka K, Maeda S. Differential diagnosis of solid pancreatic lesions using contrast-enhanced three-dimensional ultrasonography. *Abdom Imaging*. 2014; 39: 988–999.
110. Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H; Peretinoin Study Group. Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. *J Gastroenterol*. 2015 Feb;50(2):191-202
111. Okada M, Murakami T, Yada N, Numata K, Onoda M, Hyodo T, Inoue T, Ishii K, Kudo M. Comparison between T1 relaxation time of Gd-EOB-DTPA-enhanced MRI and liver stiffness measurement of ultrasound elastography in the evaluation of cirrhotic liver. *J Magn Reson Imaging*. 2015 Feb;41(2):329-38.
112. Morimoto M, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Okuwaki Y, Okuse C, Matsunaga K, Suzuki M, Morita S, Taguri M, Tanaka K. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: a propensity score analysis. *Hepatol Res*. 2015 Mar;45(3):279-87.
113. Kondo M, Morimoto M, Ishii T, Nozaki A, Fukuda H, Numata K, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Shibuya A, Okuse C, Suzuki M, Sakamaki K, Morita S, Maeda S, Tanaka K. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score-based weighting. *J Dig Dis* 2015; **16**; 143–151
114. Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, Kudo M, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, Kumada H; The Peretinoin Study Group. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. *J Gastroenterol*. 2015 Jun;50(6):667-74

115. Irie K, Morimoto M, Numata K, Kondo M, Moriya S, Shimoyama Y, Nozaki A, Goda Y, Kobayashi S, Ueno M, Ohkawa S, Tanaka K, Maeda S. Enhancement of radiofrequency ablation of the liver combined with transarterial embolization using various embolic agents. *Abdom Imaging*. 2015 Aug;40(6):1821-8.
116. Numata K. Advances in ultrasound systems for hepatic lesions in Japan. *J Medical Ultrasonics* 2015 July; 42(3): 297-301
117. Numata K, Fukuda H, Nihonmatsu H, Kondo M, Nozaki A, Chuma M, Morimoto M, Oshima T, Okada M, Murakami T, Takebayashi S, Maeda S, Inayama Y, Nakano M, Tanaka K. Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease. *Abdom Imaging* 2015 Oct;40(7):2372-83 Year of the article Abdominal Imaging 2015.
118. Inoue T, Hyodo T, Korenaga K, Murakami T, Imai Y, Higaki A, Suda T, Takano T, Miyoshi K, Koda M, Tanaka H, Iijima H, Ochi H, Hirooka M, Numata K, Kudo M. Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study. *J Gastroenterol*. Feb;51(2):144-52, 2016.
119. Nihonmatsu H, Numata K, Fukuda H, Tanaka K, Ooba M, Maeda S. Low mechanical index contrast mode versus high mechanical index contrast mode: which is a more sensitive method for detecting Sonazoid microbubbles in the liver of normal subjects? *J Med Ultrason*. Apr;43(2):211-7, 2016.
120. Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, Kudo M, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. *Hepatology*. Sep;64(3):774-84, 2016.
121. Kudo M, Ikeda M, Takayama T, Numata K, Izumi N, Furuse J, Okusaka T, Kadoya M, Yamashita S, Ito Y, Kokudo N. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. *J Gastroenterol*. Dec;51(12):1150-1160, 2016.
122. Matsumoto R, Numata K, Doba N, Hara K, Chuma M, Fukuda H, Nozaki A, Tanaka K, Ishii Y, Maeda S. A case of multiple hepatic lesions associated with methotrexate-associated lymphoproliferative disorder. *J Med Ultrason*. Oct;43(4):545-51, 2016 8
123. Sugimori K, Numata K, Okada M, Nihonmatsu H, Takebayashi S, Maeda S, Nakano M, Tanaka K. Central vascular structures as a characteristic finding of regenerative nodules using

hepatobiliary phase gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced MRI and arterial dominant phase contrast-enhanced US. *J Med Ultrason.* Jan;44(1):89-100, 2017

Year of the article Journal of Medical Ultrasonics 2017.

124. Ishii T, Numata K, Hao Y, Doba N, Hara K, Kondo M, Tanaka K, Maeda S. Evaluation of hepatocellular carcinoma tumor vascularity using contrast-enhanced ultrasonography as a predictor for local recurrence following radiofrequency ablation. *Eur J Radiol.* Apr; 89: 234–241, 2017.
125. Hao Y, Numata K, Ishii T, Fukuda H, Maeda S, Nakano M, Tanaka K. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma. *World J Gastroenterol.* May 7;23(17):3111-3121, 2017
126. Kudo M, Moriguchi M, Numata K, Hidaka H, Tanaka H, Ikeda M, Kawazoe S, Ohkawa S, Sato Y, Kaneko S, Furuse J, Takeuchi M, Fang X, Date Y, Takeuchi M, Okusaka T. S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. *Lancet Gastroenterol Hepatol.* Jun;2(6):407-417, 2017.
127. Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Yeo W, Numata K, Chopra A, Baakili A, Dela Cruz C, Zhao H, Yau T. Efficacy and Safety of Nivolumab in Asian Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): Subanalysis of the CheckMate 040 Study. *Ann Oncol.* 2017 Oct;28 Suppl 9:ix87.
128. Doba N, Fukuda H, Numata K, Hao Y, Hara K, Nozaki A, Kondo M, Chuma M, Tanaka K, Takebayashi S, Koizumi N, Kobayashi A, Tokuda J, Maeda S. A new device for fiducial registration of image-guided navigation system for liver RFA. *Int J Comput Assist Radiol Surg.* 2018 Jan;13(1):115-124
129. Kondo M, Numata K, Hara K, Nozaki A, Fukuda H, Chuma M, Maeda S, Tanaka K. Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression. *Gastroenterol Res Pract.* 2017:5728946, 2017.
130. Goda Y, Morimoto M, Irie K, Kobayashi S, Ueno M, Moriya S, Tezuka S, Ohkawa S, Morinaga S, Numata K, Tanaka K, Maeda S. Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study. *Jpn J Clin Oncol.* 2017 Dec 1;47(12):1151-1156
131. Nishigori S, Numata K, Irie K, Fukuda H, Chuma M, Maeda S. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography. *J Med Ultrason.* 2018 Jul;45(3):405-415.

Year of the article Journal of Medical Ultrasonics 2018.

132. Fukuda H, Numata K, Hara K, Nozaki A, Kondo M, Chuma M, Nakano M, Nozawa A, Maeda S, Tanaka K. Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment. *J Cancer*. 2018 Jun 14;9(13):2408-2414.
133. Miwa H, Numata K, Sugimori K, Sanga K, Hirotsu A, Tezuka S, Goda Y, Irie K, Ishii T, Kaneko T, Tanaka K, Maeda S. Differential diagnosis of gallbladder polypoid lesions using contrast-enhanced ultrasound. *Abdom Radiol (NY)*. 2019 Apr;44(4):1367-1378.
134. Duisyenbi Z, Numata K, Nihonmatsu H, Fukuda H, Chuma M, Kondo M, Nozaki A, Tanaka K, Maeda S. Comparison Between Low Mechanical Index and High Mechanical Index Contrast Modes of Contrast-Enhanced Ultrasonography: Evaluation of Perfusion Defects of Hypervascular Hepatocellular Carcinomas During the Post-Vascular Phase. *J Ultrasound Med*. 2019 Sep;38(9):2329-2338 doi: 10.1002/jum.14926. Epub 2019 Jan 17
135. Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, Maeda S, Tanaka K, Numata K. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: a Propensity Score Analysis. *Hepatology*. 2019 Jun;69(6):2533-2545
136. Chuma M, Toyoda H, Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Tanaka K, Maeda S, Sakamoto N. Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. *Hepatol Res*. 2019 Jul;49(7):810-822.
137. Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M. Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis. *J Hepatol*. 2019 Sep;71(3):543-552.
138. Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada T, Izumi N, Sumino Y, Ogawa C, Akazawa K. B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial. *Liver Cancer*. 2019 Jul;8(4):271-280.
139. Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Aikata H, Hatanaka T, Takizawa D, Matsunaga K, Okuse C, Suzuki M, Taguri M, Ishibashi T, Numata K, Maeda S, Tanaka K. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib

- alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial. *BMC Cancer*. 2019 Oct 15;19(1):954
140. Yaguchi K, Sasaki T, Ogashiwa T, Nishio M, Hashimoto Y, Ikeda A, Izumi M, Hanzawa A, Shibata N, Yonezawa H, Sakamaki K, Tateishi Y, Numata K, Maeda S, Kimura H, Kunisaki R. Correlation between the macroscopic severity of Crohn's disease in resected intestine and bowel wall thickness evaluated by water-immersion ultrasonography. *Scand J Gastroenterol*. 2019 54(11):1331-1338.
 141. Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M. Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [*J Hepatol* 71 (2019) 543-552]. *J Hepatol*. 2019 Dec;71(6):1278.
 142. Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. *J Gastroenterol*. 2020 Jan;55(1):113-122.
 143. Wang F, Numata K, Nihonmatsu H, Okada M, Maeda S. Application of new ultrasound techniques for focal liver lesions. *J Med Ultrason* 2020; 47:215–237.
 144. Sanga K, Numata K, Nihonmatsu H, Ogushi K, Fukuda H, Chuma M, Hashimoto H, Koizumi N, Maeda S, et al. Use of intra-procedural fusion imaging combining contrast-enhanced ultrasound using a perflubutane-based contrast agent and auto sweep three-dimensional ultrasound for guiding radiofrequency ablation and evaluating its efficacy in patients with hepatocellular carcinoma. *Int J Hyperthermia*. 2020;37(1):202-211.
 145. Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. *Cancers (Basel)*. 2020 Jan 26;12(2). pii: E293. doi: 10.3390/cancers12020293
 146. Miwa H, Sugimori K, Kaneko T, Ishii T, Iwase S, Irie K, Sanga K, Tozuka Y, Hirotani A, Komiyama S, Sato T, Tezuka S, Goda Y, Numata K, Maeda S. Clinical outcome of a highly flexible duodenal stent for gastric outlet obstruction: A multicenter prospective study. *JGH open* 2020 Mar 17;4(4):729-735

147. Numata K. On the occasion of publication of the feature on differential diagnosis and treatment of hepatocellular carcinoma: the role of ultrasound. *J Med Ultrason* (2001). 2020 Apr;47(2):211-213.
148. Wang F, Numata K, Yonezawa H, Sato K, Ishii Y, Yaguchi K, Kume N, Hashimoto Y, Nishio M, Nakamori Y, Ikeda A, Madarame A, Hirayama A, Ogashiwa T, Sasaki T, Jin M, Hanzawa A, Shibata N, Hashimoto S, Saigusa Y, Inayama Y, Maeda S, Kimura H, Kunisaki R. Consistency of Trans-Abdominal and Water-Immersion Ultrasound Images of Diseased Intestinal Segments in Crohn's Disease. *Diagnostics* (Basel). 2020 Apr 29;10(5): E267. doi: 10.3390/diagnostics10050267.
149. Jae Young Lee, Minami Yasunori, Byung Ihn Choi, Won Jae Lee, Yi-Hong Chou, Woo Kyoung Jeong, Mi-Suk Park, Nobuki Kudo, Min Woo Lee, Ken Kamata, Hiroko Iijima, So Yeon Kim, Kazushi Numata, Katsutoshi Sugimoto, Hitoshi Maruyama, Yasukiyo Sumino, Chikara Ogawa, Masayuki Kitano, Ijin Joo, Junichi Arita, Ja-Der Liang, Hsi-Ming Lin, Christian Nolsoe, Odd Helge Gilja, Masatoshi Kudo. The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) using Sonazoid. *Ultrasonography* 2020 Jul;39(3):191-220.
150. Wang F, Numata K, Nakano M, Tanabe M, Chuma M, Nihonmatsu H, Nozaki A, Ogushi K, Luo W, Ruan L, Okada M, Otani M, Inayama Y, Maeda S. Diagnostic Value of Imaging Methods in the Histological Four Grading of Hepatocellular Carcinoma. *Diagnostics* (Basel). 2020 May 19;10(5):321.
151. Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH. Efficacy and safety of atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma: a phase 1b study. *Lancet Oncol* 2020; 21: 808–20.
152. Satoshi Komiyama, Kazushi Numata, Satoshi Moriya, Hiroyuki Fukuda, Makoto Chuma, Shin Maeda. Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports. *World J Clin Cases* 2020 June 26; 8(12): 2574-2584 9
153. Numata K, Tanaka K, Katsube T, Ochiai T, Fukuhara T, Kano T, Osaki Y, Izumi N, Imawari M. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase 3b open-label study. *Hepatol Res*. 2020 Oct;50(10):1141-1150.
154. Satoshi Komiyama, Kazushi Numata, Katsuaki Ogushi, Satoshi Moriya, Hiroyuki Fukuda, Makoto Chuma, Shin Maeda. Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child–Pugh classification B A retrospective observational study. *Medicine* 2020 17; 99(29):e21191

155. Numata K. Contrast-enhanced ultrasound as noninvasive diagnostic images that anyone can easily understand. *J Med Ultrasonics* 2020; 47:341–345
156. Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, Park MS, Kudo N, Lee MW, Kamata K, Iijima H, Kim SY, Numata K, Sugimoto K, Maruyama H, Sumino Y, Ogawa C, Kitano M, Joo I, Arita J, Liang JD, Lin HM, Nolsoe C, Gilja OH, Kudo M. The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. *J Med Ultrasound*. 2020 May 25;28(2):59-82
157. Wang F, Numata K, Ruan L. Accurate assessment of vascularity of focal hepatic lesions in arterial phase imaging. *Radiology*. 2020 Dec;297(3):E339-E340
158. Wang F, Numata K, Nihonmatsu H, Chuma M, Moriya S, Nozaki A, Ogushi K, Fukuda H, Ruan L, Okada M, Luo W, Koizumi N, Nakano M, Otani M, Inayama Y, Maeda S. Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablation. *Int J Hyperthermia*. 2020;37(1):1149-1158
159. Yagasaki S, Koizumi N, Nishiyama Y, Kondo R, Imaizumi T, Matsumoto N, Ogawa M, Numata K. Yagasaki S, et al. Estimating 3-dimensional liver motion using deep learning and 2-dimensional ultrasound images. *Int J Comput Assist Radiol Surg*. 2020 Dec;15(12):1989-1995
160. Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S. Safety and efficacy of lenvatinib treatment in Child–Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice: a multicenter analysis. *Clinical and Experimental Gastroenterology* 2020;13:385-396
161. Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib *Sci Rep*. 2020 Oct 13;10(1):17054.
162. Numata K. On the occasion of publication of the feature on diagnosis and assessment of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis using ultrasound elastography. *J Med Ultrasonics* (2020) 47:507-509.
163. Kazuo Tarao, Akito Nozaki, Hirokazu Komatsu, Tatsuji Komatsu, Masataka Taguri, Katsuaki Tanaka, Makoto Chuma, Kazushi Numata and Shin Maeda Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm,

- Barcelona stage 0) - assessment with large number of cases. *World J Hepatol.* 2020 Nov 27;12(11):1046-1054.
164. Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouse K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis. *Hepatol Res.* 2021 Feb;51(2):201-215
 165. Miwa H, Sugimori K, Ozeki Y, Sanga K, Hirotsu A, Tezuka S, Goda Y, Numata K, Maeda S. Biliary stent removal through a transgastric fistula created with endoscopic ultrasound-guided hepaticogastrostomy. *Clin J Gastroenterol.* 2021 Feb;14(1):304-308
 166. Miwa H, Numata K, Sugimori K, Kaneko T, Maeda S. Vascular evaluation by transabdominal ultrasound for gallbladder polyp. *J Med Ultrason* 2021 Apr;48(2):159-173.
 167. Kudo M, Tsuchiya K, Kato N, Hagiwara A, Numata K, et al. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: A Phase II multicenter study. *J Gastroenterol.* 2021 Feb;56(2):181-190.
 168. Wang F, Numata K, Chuma M. The value of hepatobiliary phase in EOB-MRI in Predicting Hypervascularization Outcome of Non-hypervascular Hypointense Lesions in High-risk Patients for Hepatocellular Carcinoma. *Abdom Radiol (NY).* 2021 Jun;46(6):2527-2539.
 169. Wang F, Numata K, Takeda A, Ogushi K, Fukuda H, Hara K, Chuma M, Eriguchi T, Tsurugai Y, Maeda S. Safety and efficacy study: short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona clinical liver cancer stage 0–B1 hepatocellular carcinoma. *PLoS One.* 2021 Jan 5;16(1):e0245076.
 170. Wang F, Numata K, Chuma M, Nihonmatsu H, Moriya S, Nozaki A, Ogushi K, Fukuda H, Okada M, Ruan L, Luo W, Koizumi N, Nakano M, Otani M, Inayama Y, Maeda S. A Study on the Inconsistency of Arterial-Phase Hypervascularity Detection between Contrast-Enhanced Ultrasound using Sonazoid and Gadolinium-Ethoxybenzyl-Diethylenetriamine Penta-Acetic Acid Magnetic-Resonance Imaging of Hepatocellular-Carcinoma Lesions. *J Med Ultrason* (2001). 2021 Apr;48(2):215-224.
 171. Feiqian Wang, Kazushi Numata, Masahiro Okada, Makoto Chuma, Hiromi Nihonmatsu, Satoshi Moriya, Akito Nozaki, Katsuaki Ogushi¹, Wen Luo⁴, Litao Ruan², Masayuki Nakano⁵, Masako Otani⁶, Yoshiaki Inayama⁶, Shin Maeda⁷ Comparison of Sonazoid Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid MRI for the

Histological Diagnosis of Hepatocellular Carcinoma. Quant Imaging Med Surg. 2021 Jun;11(6):2521-2540 3.837

172. Miwa H, Sugimori K, Ishii T, Funaoka A, Tsuchiya H, Suzuki Y, Sugimori M, Nishimura M, Tozuka Y, Komiyama S, Sato T, Kaneko T, Numata K, Maeda S. Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas. Intern Med. 2021 Aug 15;60(16):2607-2612. 10
173. Akito Nozaki" "Makoto Chuma" "Koji Hara" "Satoshi Moriya" "Hiroyuki Fukuda" "Kazushi Numata" "Katsuaki Tanaka" "Manabu Morimoto" "Kentarō Sakamaki" "Takeharu Yamanaka" "Masaaki Kondo" "Shin Maeda" Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: a prospective observational study. Medicine 2021 Mar 26;100(12):e25110
174. Akihiro Funaoka, Kazushi Numata, Atsuya Takeda, Yusuke Saigusa, Yuichirou Tsurugai, Hiromi Nihonmatsu1, Makoto Chuma, Hiroyuki Fukuda, Masahiro Okada, Masayuki Nakano, and Shin Maeda. Use of contrast-enhanced ultrasound with Sonazoid for evaluating the radiotherapy efficacy for hepatocellular carcinoma. Diagnostics (Basel). 2021 Mar 9;11(3):486.
175. Masatoshi Kudo, Ana Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Mirelis Acosta-Rivera, Su-Pin Choo, Anthony B. El-Khoueiry, Ryoko Kuromatsu, Bassel El-Rayes, Kazushi Numata, Yoshito Itoh, Francesco Di Costanzo, Oxana Crysler, Maria Reig, Yun Shen, Jaclyn Neely, Marina Tschalka, Tami Wisniewski, Bruno Sangro CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021 Sep;75(3):600-609.
176. Ozeki Y, Miwa H, Sugimori K, Goda Y, Hirotsu A, Sanga K, Tezuka S, Numata K, Sekikawa Z, Maeda S. Hemoperitoneum due to a ruptured right gastroepiploic artery following non-interventional endoscopic ultrasonography: a case report. Clin J Gastroenterol. 2021 Jun 18. doi: 10.1007/s12328-021-01466-8 11
177. Tarao K, Nozaki A, Komatsu H, Komatsu T, Taguri M, Tanaka K, Yoshida T, Koyasu H, Chuma M, Numata K, Maeda S. Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma. World J Hepatol. 2021 Jun 27;13(6):699-708.
178. Satoshi Komiyama; Kazushi Numata; Katsuaki Ogushi; Makoto Chuma; Reiko Tanaka; Sawako Chiba; Masako Otani; Yoshiaki Inayama; Masayuki Nakano; Shin Maeda. Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. Diagnostics 2021, Volume 11, Issue 8, 1394 12
179. Numata K. Abdominal Ultrasound and Treatment of Hepatocellular Carcinoma. Diagnostics (Basel). 2021 Jul 15;11(7):1268. doi: 10.3390/diagnostics11071268.

180. Feiqian Wang; Kazushi Numata; Atsuya Takeda; Katsuaki Ogushi; Hiroyuki Fukuda; Hiromi Nihonmatsu; Koji Hara; Makoto Chuma; Yuichirou Tsurugai; Shin Maeda. Optimal Application of Stereotactic Body Radiotherapy and Radiofrequency Ablation Treatment for Different Multifocal Hepatocellular Carcinoma Lesions in Patients with Barcelona Clinic Liver Cancer Stage A4–B1: A Pilot Study. *BMC Cancer*. 2021 Oct 30;21(1):1169. doi: 10.1186/s12885-021-08897-z.
181. Fukushima T, Morimoto M, Ueno M, Kubota K, Uojima H, Hidaka H, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S. Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting. *JGH Open*. 2021 Dec 17;6(1):29-35.
182. Momoko Matsuyama, Norihiro Koizumi, Akihide Otsuka, Kento Kobayashi, Shiho Yagasaki, Yusuke Watanabe, Jiayi Zhou¹, Yu Nishiyama, Naoki Matsumoto, Hiroyuki Tsukihara, Kazushi Numata. A novel complementation method of an acoustic shadow region utilizing a convolutional neural network for ultrasound-guided therapy. *International Journal of Computer Assisted Radiology and Surgery*. 2022 Jan;17(1):107-119.
183. Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis. *Hepatol Res*. 2022 Mar;52(3):269-280
184. Ogushi K, Chuma M, Numata K, Nozaki A, Moriya S, Uojima H, Kondo M, Morimoto M, Maeda S. Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients. *Eur J Gastroenterol Hepatol*. 2022 Jul 1;34(7):774-781.
185. Masahiro Okada, Kazushi Numata, Hiromi Nihonmatsu, Kengo Tomita, Atsuya Takeda, Tomoko Hyodo, Takahisa Eriguchi, Masayuki Nakano. Pathological appearance of focal liver reactions after stereotactic body radiotherapy for hepatocellular carcinoma. *Diagnostics (Basel)*. 2022 Apr 25;12(5):1072.

186. Satoshi Kobayashi^{1*}, Taito Fukushima¹, Makoto Ueno¹, Satoshi Moriya², Makoto Chuma², Kazushi Numata², Kota Tsuruya³, Shunji Hirose³, Tatehiro Kagawa³, Nobuhiro Hattori⁴, Tsunamasa Watanabe⁴, Kotaro Matsunaga⁴, Michihiro Suzuki⁴, Haruki Uojima⁵, Hisashi Hidaka⁵, Chika Kusano⁵, Motoko Suzuki⁶ and Manabu Morimoto¹ Dr Kobayashi A Prospective Observational Cohort Study of Lenvatinib as Initial Treatment in Patients with BCLC-Defined Stage B Hepatocellular Carcinoma. BMC cancer (2022) 22:517

187. Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Curr Oncol. 2022 May 4;29(5):3259-3271.

188. Feiqian Wang, Kazushi Numata, Satoshi Komiyama, Haruo Miwa, Kazuya Sugimori, Katsuaki Ogushi, Satoshi Moriya, Akito Nozaki, Makoto Chuma, Litao Ruan, Shin Maeda. Combination Therapy with Lenvatinib and Radiofrequency Ablation for Patients with Intermediate-stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh Class A Liver function: A Pilot Study. Frontiers in Oncology 2022, 12, 843680.

189. Miwa H, Sugimori K, Tsuchiya H, Sugimori M, Nishimura M, Tozuka Y, Komiyama S, Sato T, Kaneko T, Numata K, Maeda S. Novel clip device for prevention of bleeding after endoscopic papillectomy. DEN open. 2022 Apr; 2(1): e51

190. Ying Zhang, Kazushi Numata, Yuewu Du, Shin Maeda. Contrast agents for Hepatocellular carcinoma (HCC) imaging: value and progression. Frontiers in Oncology 2022 Jun 2;12:921667.

191. Kawamura A, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Take A, Sakaguchi Y, Numata K, Kako M, Nozaki A, Azuma S, Horio K, Kusano C, Atsuda K. The change rate in serum nitric oxide may affect lenvatinib therapy in

hepatocellular carcinoma. *BMC Cancer*. 2022 Aug 23;22(1):912.

192. Zhou J, Koizumi N, Nishiyama Y, Kogiso K, Ishikawa T, Kobayashi K, Watanabe Y, Fujibayashi T, Yamada M, Matsuyama M, Tsukihara H, Tsumura R, Yoshinaka K, Matsumoto N, Ogawa M, Miyazaki H, Numata K, Nagaoka H, Iwai T, Iijima H. A VS ultrasound diagnostic system with kidney image evaluation functions. *Int J Comput Assist Radiol Surg*. 2023 Feb;18(2):227-246.
192. Numata K, Wang F. New developments in ablation therapy for hepatocellular carcinoma: combination with systemic therapy and radiotherapy. *Hepatobiliary Surg Nutr*. 2022 Oct;11(5):766-769.
193. Ideno N, Nozaki A, Chuma M, Ogushi K, Hara K, Moriya S, Fukuda H, Numata K, Maeda S. Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection. *Eur J Gastroenterol Hepatol*. 2023 Feb 1;35(2):219-226.
194. Wang F, Numata K, Nihonmatsu H, Chuma M, Ideno N, Nozaki A, Ogushi K, Tanabe M, Okada M, Luo W, Nakano M, Otani M, Inayama Y, Maeda S. Added Value of Ultrasound-Based Multimodal Imaging to Diagnose Hepatic Sclerosed Hemangioma before Biopsy and Resection. *Diagnostics (Basel)*. 2022 Nov 16;12(11):2818.
195. Naoya Kato, Masatoshi Kudo, Kaoru Tsuchiya, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Naohiro Okano, Masafumi Ikeda, Manabu Morimoto, Shingo Kuroda, Akiko Kimura. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: final results of a multicenter phase 2 study. *Hepatol Res* 2023 May;53(5):409-416.
196. Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, Ogushi K, Arase Y, Take A, Sakaguchi Y, Tomoko A, Nishigori S, Wanatanbe T, Numata K, Morimoto M, Kagawa T, Kako M, Kusano C. Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy. *Eur J Gastroenterol Hepatol*. 2023 Aug 1;35(8):865-873.
197. Taito Fukushima, Manabu Morimoto, Satoshi Kobayashi, Kousuke Kubota, Haruki

- Uojima, Hisashi Hidaka, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Kotaro Matsunaga, Tsunamasa Watanabe, Katsuaki Tanaka, Shin Maeda. Association Between Immune-Related Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. *Oncologist*. 2023 Jul 5;28(7):e526-e533.
198. Yoshiko Doi, Yasushi Nagata, MD, Yasuo Matsumoto, Kazushi Numata, Ryuu Sasaki, Takashi Yamada, Kouji Inaba, Toshiyuki Imagunbai, Norio Katoh, Tadamasa Yoshitake, Takuya Shimizuguchi, Den Fujioka, Minoru Inoue, MD, Yutarou Koide, Tomoki Kimura, Yoshinori Ito. Multicenter retrospective study of Stereotactic body radiotherapy for patients with newly diagnosed small hepatocellular carcinoma. *Hepatol Res*. 2023 Aug;53(8):749-760.
199. Fujibayashi T, Koizumi N, Nishiyama Y, Watanabe Y, Zhou J, Matsuyama M, Yamada M, Tsumura R, Yoshinaka K, Matsumoto N, Tsukihara H, Numata K. Study on method of organ section retention and tracking through deep learning in automated diagnostic and therapeutic robotics. *Int J Comput Assist Radiol Surg*. 2023 Nov;18(11):2101-2109.
200. Miwa H, Sugimori K, Matsuoka Y, Endo K, Oishi R, Nishimura M, Tozuka Y, Kaneko T, Numata K, Maeda S. Loop technique for guidewire manipulation during endoscopic ultrasound-guided hepaticogastrostomy. *JGH Open*. 2023 Apr 12;7(5):358-364.
201. Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. *Lancet*. 2023 Nov 18;402(10415):1835-1847.
202. Miwa H, Sugimori K, Yoshimura H, Endo K, Oishi R, Funaoka A, Tsuchiya H, Kaneko T, Numata K, Maeda S. Novel peroral cholangioscopy-guided electrohydraulic lithotripsy for difficult stones. *J Hepatobiliary Pancreat Sci*. 2024 Feb;31(2):e8-e10.

203. Masafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, Masatoshi Kudo, Yoshitaka Inaba, Manabu Morimoto, Kaoru Tsuchiya, Satoshi Shimizu, Yasushi Kojima, Atsushi Hiraokj, Kazuhiro Nouse, Hiroshi Aikata, Kazushi Numata, Tosiya Sato, Takuji Okusaka, Junji Furuse. Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD. *Liver Cancer*. 2023 Jul 7;13(2):193-202.
204. Feiqian Wang, Kazushi Numata, Hua Liang, Hiromi Tsuchiya, Litao Ruan, Mikiko Tanabe, Xiaofang Bai. The value of contrast-enhanced ultrasonography and contrast-enhanced computed tomography in the diagnosis of hepatic angiosarcoma. *Front Oncol*. 2023 Dec 1;13:1283544.
205. Satoshi Kobayashi^a, Taito Fukushima^a, Makoto Ueno^a, Makoto Chuma^b, Kazushi Numata^b, Kota Tsuruya^c, Yosataka Arase^c, Shunji Hirose^c, Tatehiro Kagawa^c, Nobuhiro Hattori^d, Tsunamasa Watanabe^d, Kotaro Matsunaga^d, Haruki Uojima^e, Hisashi Hidaka^e, Chika Kusano^e, Manabu Morimoto^a, Shin Maeda. Progression Pattern and Post-progression Survival following Atezolizumab and Bevacizumab Treatment in Advanced Hepatocellular Carcinoma. *Liver Int*. 2024 Jun;44(6):1343-1350. doi: 10.1111/liv.15825. Online ahead of print.
206. Xian-Yang Qin, Yohei Shirakami, Masao Honda, Shiou-Hwei Yeh, Ya-Yun Lai, Chiao-Ling Li, Feifei Wei, Yutaka Furutani, Kazuaki Chayama, Masaru Enomoto, Kazushi Numata, Ryosuke Tateishi, Kazunori Kawaguchi, Tatsuya Yamashita, Shuichi Kaneko Katsuya Nagaoka, Yutaka Sasaki, Koichi Miura, Takahiro Masaki, Tomokazu Matsuura, Masahito Shimizu, Pei-Jer Chen and Soichi Kojima. Serum MYCN as a biomarker for the prediction of therapeutic response and prognosis of hepatocellular carcinoma. *Int J Cancer*. 2024 Aug 1;155(3):582-594. doi: 10.1002/ijc.34893.
207. Miwa H, Sugimori K, Yonei S, Yoshimura H, Endo K, Oishi R, Funaoka A, Tsuchiya H, Kaneko T, Numata K, Maeda S. Differential Diagnosis of Solid Pancreatic Lesions Using Detective Flow Imaging Endoscopic Ultrasonography. *Diagnostics (Basel)*. 2024 Apr 24;14(9):882
208. Katsuki Yaguchi 1, 2) *, Reiko Kunisaki 1, 2) *, Sho Sato 3), Kaori Hirai 3), Misato Izumi 3), Yoshimi Fukuno 3), Mika Watanabe 3), Akiho Hanzawa 3), Hiromi Yonezawa 3),

- Rongrong Wo 1), Yurika Nishikawa 1), Yusuke Matsune 1), Shunsuke Shibui 1), Yoshinori Nakamori 1, 2) , Masafumi Nishio 1, 2) , Mao Matsubayashi 1), Ayako Fujii 1), Kenichiro Toritani 1), Hideaki Kimura 1), Eita Kumagai 4), Yukiko Kasahara 4), Yoshiaki Inayama 4), Satoshi Fujii 4), Toshiaki Ebina 3), Kazushi Numata 5,2), Shin Maeda 2) Intestinal ultrasound for intestinal Behçet's disease reflects endoscopic activity and histopathological findings. *Intest Res.* 2024 Jul 16. doi: 10.5217/ir.2023.00129.
209. Feiqian Wang, Kazushi Numata, Akihiro Funaoka, Xi Liu, Takafumi Kumamoto, Kazuhisa Takeda, Makoto Chuma, Akito Nozaki, Litao Ruan, and Shin Maeda Establishment and comparison of nomogram prediction model of contrast-enhanced ultrasound and Gd-EOB-DTPA-enhanced MRI for vessels encapsulating tumor clusters pattern of hepatocellular carcinoma. Sub-headings: diagnosis of vessels encapsulating tumor clusters pattern of hepatocellular carcinoma. *Biosci Trends.* 2024 Jul 9;18(3):277-288.
210. Makoto Chuma,¹ Haruki Uojima,² Hidenori Toyoda,³ Atsushi Hiraoka,⁴ Yoshitake Arase,⁵ Masanori Atsukawa,⁶ Tomomi Okubo,⁶ Norio Itokawa,⁷ Toshifumi Tada,⁸ Kazushi Numata,¹ Makoto Sugimori,^{1,†} Akito Nozaki,¹ Satoshi Yasuda, Hisashi Hidaka,³ Takashi Kumada,^{3,9,†} Kusano Chikako,² Tatehiro Kagawa,⁵ and Shin Maeda¹⁰
Clinical significance of circulating biomarkers of immune checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma. *Hepatol Int.* 2024 Jul 4. doi: 10.1007/s12072-024-10680-8
211. Ying Zhang, Numata K, et al. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A Multicenter Study. *Hepatol Res.* 2024 Jul 2. doi: 10.1111/hepr.14089
212. Wang F, Numata K, Akihiro Funaoka, Takafumi Kumamoto, Kazuhisa Takeda, Makoto Chuma, Akito Nozaki, Shin Maeda. A strategy based on dynamic contrast-enhanced imaging for preoperative diagnosis of microvascular invasion in hepatocellular carcinoma. *EJR* open accepted 1/July/2024. 2024 Jul 8;13:100587. doi: 10.1016/j.ejro.2024.100587. eCollection 2024 Dec.
213. Litao Ruan, Jingtong Yu, Xingqi Lu, Kazushi Numata, Dong Zhang, Xi Liu, Xiaojing Li, Mingwei Zhang, Feiqian Wang. A nomogram based on features of ultrasound and contrast-enhanced CT to predict vessels encapsulating tumor clusters pattern

of hepatocellular carcinoma. *Ultrasound Med Biol*. 2024 Sep 16;S0301-5629(24)00331-4.

214. Lu XQ, Yu JT, Ruan LT, Numata K, Zhang D, Wang FQ. The value of Contrast-enhance ultrasound in the diagnosis of hepatic post-transplant lymphoproliferative disease: Four case reports. *Intractable & Rare Diseases Research* DOI: 10.5582/irdr.2024.01032
215. Maruyama H, Minami Y, Sugimoto K, Funaoka A, Numata K. Ablation manual for liver cancer. *J Med Ultrason* (2001). 2025 Jan;52(1):27-53.
216. Masatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, Kazushi Numata, Hiroyuki Marusawa, Tetsuya Hosaka, Naoya Kato, Masayuki Kurosaki, Manabu Morimoto, Tatsuya Yamashita, Hironori Koga, Tsutomu Masaki, Naoyoshi Yatsuzuka, Masato Suzuki, Satoshi Nagao, Shuichi Kaneko, Hiromitsu Kumada. First-line Lenvatinib Plus Pembrolizumab for Hepatocellular Carcinoma: Post Hoc Analysis of Japanese Patients From the Phase 3 LEAP-002 Trial. *Liver Cancer*. 1–13.<https://doi.org/10.1159/000542572>
217. Ying Zhang, Kazushi Numata, Hiromi Nihonmatsu, Akihiro Funaoka, Haruo Miwa, Ritsuko Oishi, Akito Nozaki, Shin Maeda. Enhancing Deep-Seated Hepatocellular Carcinoma Detection: Assessing the Added Value of Additional High Mechanical Index Setting in Sonazoid-based Contrast Enhanced Ultrasound during Post-Vascular Phase. *J Med Ultrason* 2025 Jan;52(1):105-117.
218. Masahiro Okada, Ryoji Aoki, Yujiro Nakazawa, Kenichiro Tago, Kazushi Numata. Computed tomography and magnetic resonance imaging of hepatocellular carcinoma and liver cirrhosis. *Gastroenterology Insights* in press 17 Oct 2024
219. Makoto Sugimori* 1, 2, 4, Masaki Nishimura* 2, Kazuya Sugimori², Shoichiro Yonei², Yuto Matsuoka², Yuto Yoshimura², Kazuki Endo², Ritsuko Oishi², Hiromi Tsuchiya², Sho Tsuyuki^{1, 2}, Akane Hirotsu^{1, 2}, Satoshi Komiyama², Haruo Miwa², Takashi Kaneko², Miyako Kosugi³, Fukiko Kobayashi⁴, Haruka Tanaka⁴, Teruaki Koda^{4, 5}, Akiko Takase^{4, 5}, Haruka Hirose⁴, Yoshiaki Inayama^{4, 5}, Akito Nozaki², Kazushi Numata², Chikara Kunisaki^{1, 6}, Shin Maeda⁷. A case of advanced biliary tract cancer with EGFR amplification that responded to Necitumumab. *Cancer Reports* 2024 Nov;7(11):e70053.

220. Yoon Jun Kim¹, Philippe Merle², Richard S. Finn³, Masatoshi Kudo⁴, Heinz-Josef Klumpen⁵, Ho Yeong Lim⁶, Masafumi Ikeda⁷, Alessandro Granito⁸, Gianluca Masi⁹, René Gerolami¹⁰, Sung Bum Cho¹¹, Chih-Hung Hsu¹², Yi-Hsiang Huang¹³, Long-Bin Jeng¹⁴, Do Young Kim¹⁵, Shi-Ming Lin¹⁶, Matthias Pinter¹⁷, Guoliang Shao¹⁸, Naoya Kato¹⁹, Masayuki Kurosaki²⁰, Kazushi Numata²¹, Kung-Kai Kuo²², Yilei Mao²³, Yih-Jyh Lin²⁴, Kangshun Zhu²⁵, Philip Twumasi-Ankrah²⁶, Javeed Khan²⁷, Maria Awan²⁶, Kirhan Ozgurdal²⁸, Shukui Qin² Regorafenib for hepatocellular carcinoma in real-world practice (REFINE): a prospective, observational study. Liver cancer DOI: 10.1159/000542285
221. Wang F, Yu J, Lu X, Numata K, Ruan L, Zhang D, Liu X, Li X, Wan M, Zhang W, Zhang G. Relationship between contrast-enhanced ultrasound combined with ultrasound resolution microscopy imaging and histological features of hepatocellular carcinoma. Abdominal Radiology 2025 Feb 10. doi: 10.1007/s00261-025-04825-y

BOOK

1. Book: Kazushi Numata, Wen Luo, Manabu Morimoto, Hiroyuki Fukuda, Naoto Sato and Katsuaki Tanaka (2011). Clinical Usefulness of Contrast-Enhanced Three-Dimensional Ultrasound Imaging with Sonazoid for Hepatic Tumor Lesions, Ultrasound Imaging, chapter 9, p 151-170, Masayuki Tanabe (Ed.), ISBN: 978-953-307-239-5, InTech, Available from: <http://www.intechopen.com/articles/show/title/clinical-usefulness-of-contrast-enhanced-three-dimensional-ultrasound-imaging-with-sonazoid-for-hepa>

特許

- ・小泉憲裕, 栢菅 篤, 富田恭平, 細井泉澄, 西山 悠, 月原弘之, 宮寄英世, 福田浩之, 沼田和司, 葭仲 潔, 東 隆, 杉田直彦, 本間之夫, 松本洋一郎, 光石 衛, "生体内運動追跡装置", 特願2017-040348, 2017.3.3.
- ・小泉憲裕, 栢菅 篤, 富田恭平, 細井泉澄, 西山 悠, 月原弘之, 宮寄英世, 福田浩之, 沼田和司, 葭仲 潔, 東 隆, 杉田直彦, 本間之夫, 松本洋一郎, 光石 衛, "生体内運動追跡装置", 出願番号 (米国) : US15/876233, 2018.1.22.